Safety committee raises concern over ArQule's liver cancer drug

(Reuters) - Drugmaker ArQule Inc said a late-stage trial of its liver cancer drug showed high incidence of low white blood cell count in patients, leading to an independent safety committee recommending the company lower the drug dose. ArQule shares fell nearly 20 percent to $2.24 on the Nasdaq in early morning trade on Tuesday. The Data Monitoring Committee recommended that the study dose be reduced from 240 mg twice daily to 120 mg, and the patients be monitored to confirm the safety profile of the lower dose. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/safety-committee-raises-concern-over-arqules-liver-cancer-133826835--finance.html